mutation de la perte de fonction NF1
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-NF1-MUTATION |
|---|---|
| Type | Biomarqueur |
| Alias | NF1 LOFmutation NF1perte de neurofibromeМутація NF1 (втрата функції) |
| État | reviewed 2026-04-29 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-CIVIC SRC-NCCN-MELANOMA-2025 |
Données biomarqueurs
| Type de biomarqueur | gene_mutation |
|---|---|
| Détails de la mutation | {"functional_impact": "loss_of_function", "gene": "NF1", "variant_type": "loss-of-function — frameshift / nonsense / splice / large deletion (germline NF1 syndrome or somatic)"} |
| Mesure | MéthodePanneaux NGS (tumoral ou germinatif) détectant des événements tronquants / épissures / CNV; IHC pour la perte de neurofibrome est de niveau de recherche seulement Unitéscategorical (mutated | wild-type) |
| Biomarqueurs connexes | BIO-BRAF-V600E |
Notes
NF1 encodes neurofibromin, a RAS-GAP tumor suppressor. Loss-of-function events activate RAS/MAPK signaling. **Melanoma sub-classification (TCGA Cell 2015):** four genomic subtypes — BRAF-mutant, RAS-mutant, NF1-mutant, triple wild-type. NF1-mutant melanomas (~14%) are typically: - cutaneous, sun-exposed sites with high UV signature mutational burden - older patients - frequently co-occur with RASopathy-pattern alterations - generally lack canonical BRAF V600 / NRAS Q61 drivers **Therapeutic relevance:** - No tumor-type-agnostic NF1-directed targeted therapy approved (2026). - MEK inhibitor sensitivity reported in plexiform neurofibroma (selumetinib FDA-approved for pediatric NF1 plexiform NF, 2020) and explored in NF1-mutant cutaneous melanoma (off-label, evidence emerging). - High TMB common in UV-driven NF1-mutant melanoma → ICI candidate. Outside melanoma: NF1 mutation is the defining lesion in neurofibromatosis type 1 (germline) and recurs somatically in glioblastoma, MPNST, juvenile myelomonocytic leukemia (JMML), AML, ovarian, lung adenocarcinoma. Lineage drives interpretation. multi_allele_mvp skip-reason: tumor-suppressor with no single canonical actionable variant — many...
Utilisé par
No reverse references found in the YAML corpus.